Literature DB >> 31771890

Transradial and Transfemoral Uterine Fibroid Embolization Comparative Study: Technical and Clinical Outcomes.

Masoud Nakhaei1, Alireza Mojtahedi1, Salomao Faintuch1, Ammar Sarwar1, Olga R Brook2.   

Abstract

PURPOSE: To compare clinical and technical outcomes of transradial (TRA) uterine artery embolization (UAE) with those of the transfemoral (TFA) approach.
MATERIALS AND METHODS: Consecutive patients who underwent UAE with TRA and TFA in an academic hospital between May 2014 and June 2018 were included in this study. The ability to perform the procedure as planned, complication rates, and reduction in uterine volume, fibroid enhancement, and symptomatic improvement were compared using descriptive statistics, Student t-test, and chi-square test.
RESULTS: There were 91 patients in the TFA group and 91 patients in the TRA group, with 1 crossover to TFA due to vasospasm (1 of 91; 1%). The tallest patient in the TRA UAE group was 178 cm and 4 patients taller than 178 cm in the TFA UAE group. Larger particles (900-1,200 μm) were more often used in the TFA group than in the TRA group (P < .001). There were similar low rates of minor access site complications. In the TFA group (6 of 91, 7%), 5 patients had groin hematomas, and 2 patients had groin pain compared to the TRA group (5 of 91, 5%): in which 4 patients had transient focal occlusion of the radial artery and 1 patient had focal pain, all of which resolved with conservative management. There were similar rates of uterine volume reduction in 40% ± 17% in the TFA versus 36% ± 16% in the TRA group (P = .22) and no residual enhancement in 49 of 58 [84%] in the TFA group versus 66 of 77 [86%] in the TRA group (P = .84). There were similar reductions in modifying symptoms (60 of 64 [94%] in the TRA group; and 37 of 40 [93%] in the TFA group; P = NS) was noted at follow-up.
CONCLUSIONS: Transradial UAE in women up to 178 cm tall and transfemoral UAE have similar technical and clinical outcomes, with low rates of access site complications.
Copyright © 2019 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31771890     DOI: 10.1016/j.jvir.2019.08.016

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  6 in total

1.  Comparison of transradial and transfemoral access for transcatheter arterial embolization of iatrogenic renal hemorrhage.

Authors:  Chuanwu Cao; So-Yeon Kim; Gun Ha Kim; Ji Hoon Shin; In Chul Nam; Meshari Alali; Hee Ho Chu; Heung-Kyu Ko
Journal:  PLoS One       Date:  2021-08-20       Impact factor: 3.240

Review 2.  Managing Postembolization Syndrome-Related Pain after Uterine Fibroid Embolization.

Authors:  Patricia Chan; Kirema Garcia-Reyes; Julie Cronan; Janice Newsome; Zachary Bercu; Bill S Majdalany; Neil Resnick; Judy Gichoya; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2021-08-10       Impact factor: 1.780

Review 3.  Current Strategies for Prevention of Infection After Uterine Artery Embolisation.

Authors:  Matthew Lukies; Warren Clements
Journal:  Cardiovasc Intervent Radiol       Date:  2022-05-16       Impact factor: 2.797

Review 4.  Update on Transradial Access for Percutaneous Transcatheter Visceral Artery Embolization.

Authors:  Hee Ho Chu; Jong Woo Kim; Ji Hoon Shin; Soo Buem Cho
Journal:  Korean J Radiol       Date:  2020-08-28       Impact factor: 3.500

Review 5.  Transradial Embolization, an Underused Type of Uterine Artery Embolization Approach: A Systematic Review.

Authors:  Loredana Maria Maria Himiniuc; Mara Murarasu; Bogdan Toma; Razvan Popovici; Ana-Maria Grigore; Ioana-Sadiye Scripcariu; Mihaela Oancea; Mihaela Grigore
Journal:  Medicina (Kaunas)       Date:  2021-01-20       Impact factor: 2.430

6.  Feasibility of Outpatient Transradial Prostatic Artery Embolization and Safety of a Shortened Deflation Protocol for Hemostasis.

Authors:  Gregory Amouyal; Louis Tournier; Constance de Margerie-Mellon; Damien Bouda; Atanas Pachev; Jessica Assouline; Cédric de Bazelaire; Florent Marques; Solenne Le Strat; François Desgrandchamps; Eric De Kerviler
Journal:  J Pers Med       Date:  2022-07-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.